Compare · MEDS vs VCYT

MEDS vs VCYT

Side-by-side comparison of DataMeds AI Inc. (MEDS) and Veracyte Inc. (VCYT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. MEDS focuses on Other Pharmaceuticals, while VCYT focuses on Medical Specialities.
  • VCYT is the larger of the two at $1.94B, about 625.0x MEDS ($3.1M).
  • Over the past year, MEDS is down 98.0% and VCYT is down 38.8% - VCYT leads by 59.2 points.
  • VCYT has been more active in the news (12 items in the past 4 weeks vs 5 for MEDS).
  • VCYT has more recent analyst coverage (25 ratings vs 1 for MEDS).
PerformanceMEDS-98.02%VCYT-38.83%
2025-11-17+0.00%2026-11-16
MetricMEDSVCYT
Company
DataMeds AI Inc.
Veracyte Inc.
Price
-
-
Market cap
$3.1M
$1.94B
1M return
-77.82%
-44.40%
1Y return
-98.02%
-38.83%
Industry
Other Pharmaceuticals
Medical Specialities
Exchange
NASDAQ
NASDAQ
IPO
2013
News (4w)
5
12
Recent ratings
1
25
MEDS

DataMeds AI Inc.

DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.

VCYT

Veracyte Inc.

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Latest MEDS

Latest VCYT